IL-1-话题@MedSci

#IL-1#

184篇内容 | 1690人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1508333, encodeId=2c021508333fe, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=Am J Clin Dermatol：IL-12/23、IL-17和IL-23抑制剂治疗银屑病的药物存活率, objectType=article, longId=736657, objectId=c691e366579d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c691e366579d, replyNumber=0, likeNumber=40, createdTime=2022-08-24, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c691e366579d, moduleTitle=Am J Clin Dermatol：IL-12/23、IL-17和IL-23抑制剂治疗银屑病的药物存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c691e366579d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508332, encodeId=26141508332e0, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=IL-13通过抑制肺动脉平滑肌细胞增殖、调节巨噬细胞浸润缓解特发性肺动脉高压, objectType=article, longId=735829, objectId=1207e358295e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1207e358295e, replyNumber=0, likeNumber=39, createdTime=2022-08-15, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1207e358295e, moduleTitle=IL-13通过抑制肺动脉平滑肌细胞增殖、调节巨噬细胞浸润缓解特发性肺动脉高压, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1207e358295e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508331, encodeId=079a150833185, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=ARD：IL-12/23通路抑制剂优特克单抗或TNFi 治疗银屑病关节炎患者的持久性和有效性相当, objectType=article, longId=730741, objectId=13a2e30741f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13a2e30741f5, replyNumber=0, likeNumber=40, createdTime=2022-06-30, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13a2e30741f5, moduleTitle=ARD：IL-12/23通路抑制剂优特克单抗或TNFi 治疗银屑病关节炎患者的持久性和有效性相当, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13a2e30741f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508330, encodeId=e0e7150833013, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=A&R：CD163+ M2巨噬细胞通过Toll样受体7/IL-1受体相关激酶4/NF-κB信号通路促进IgG4相关疾病的纤维化, objectType=article, longId=726552, objectId=259ee265523c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=259ee265523c, replyNumber=0, likeNumber=27, createdTime=2022-05-12, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=259ee265523c, moduleTitle=A&R：CD163+ M2巨噬细胞通过Toll样受体7/IL-1受体相关激酶4/NF-κB信号通路促进IgG4相关疾病的纤维化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=259ee265523c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508329, encodeId=6e6615083293a, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=A&R: IL-13Rα1介导的信号传导调节年龄相关/自身免疫 B 细胞扩增和狼疮发病机制, objectType=article, longId=725909, objectId=b6c4e25909db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6c4e25909db, replyNumber=0, likeNumber=38, createdTime=2022-05-02, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6c4e25909db, moduleTitle=A&R: IL-13Rα1介导的信号传导调节年龄相关/自身免疫 B 细胞扩增和狼疮发病机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6c4e25909db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508328, encodeId=106015083283c, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=托法替尼对银屑病患者皮肤和血液中IL-12/IL-23 p40亚单位的抑制依赖于树突状细胞中活性干扰素-γ信号传导研究, objectType=article, longId=725659, objectId=d704e2565909, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d704e2565909, replyNumber=0, likeNumber=39, createdTime=2022-04-29, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d704e2565909, moduleTitle=托法替尼对银屑病患者皮肤和血液中IL-12/IL-23 p40亚单位的抑制依赖于树突状细胞中活性干扰素-γ信号传导研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d704e2565909)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508327, encodeId=9900150832e02, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=Crit Care：伴有AKI的危重患者血清IL-17水平较高且与患者较差预后相关, objectType=article, longId=724388, objectId=4e89e24388b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e89e24388b1, replyNumber=0, likeNumber=45, createdTime=2022-04-17, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e89e24388b1, moduleTitle=Crit Care：伴有AKI的危重患者血清IL-17水平较高且与患者较差预后相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e89e24388b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508326, encodeId=cc73150832606, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=Front Immunol：IL-17加重慢性阻塞性肺疾病急性加重期铜绿假单胞菌呼吸道感染, objectType=article, longId=300605, objectId=849a30060505, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=849a30060505, replyNumber=0, likeNumber=38, createdTime=2022-03-14, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=849a30060505, moduleTitle=Front Immunol：IL-17加重慢性阻塞性肺疾病急性加重期铜绿假单胞菌呼吸道感染, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=849a30060505)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508325, encodeId=b4501508325b9, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=Br J Dermatol：Brodaluma阻断 IL-17RA可减少化脓性汗腺炎皮肤和血清中的炎症通路, objectType=article, longId=300087, objectId=8e5930008e1a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e5930008e1a, replyNumber=0, likeNumber=40, createdTime=2022-03-06, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e5930008e1a, moduleTitle=Br J Dermatol：Brodaluma阻断 IL-17RA可减少化脓性汗腺炎皮肤和血清中的炎症通路, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e5930008e1a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508324, encodeId=3fb5150832488, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=Front Immunol：大疱性类天疱疮的IL-13遗传易感性：治疗的潜在目标和预后标志物, objectType=article, longId=295764, objectId=5ef2295e6419, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ef2295e6419, replyNumber=0, likeNumber=29, createdTime=2022-02-17, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ef2295e6419, moduleTitle=Front Immunol：大疱性类天疱疮的IL-13遗传易感性：治疗的潜在目标和预后标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ef2295e6419)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508323, encodeId=31f61508323de, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=Nature Medicine：令人兴奋：IL-15超级激动剂治疗艾滋病的1期临床结果发布, objectType=article, longId=295116, objectId=8f862951163b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f862951163b, replyNumber=0, likeNumber=40, createdTime=2022-02-05, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f862951163b, moduleTitle=Nature Medicine：令人兴奋：IL-15超级激动剂治疗艾滋病的1期临床结果发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f862951163b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508322, encodeId=dbce1508322f6, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=UCB正在寻求IL-17A 和 IL-17F 双重抑制剂Bimzelx在银屑病关节炎中的批准, objectType=article, longId=294569, objectId=656829456957, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=656829456957, replyNumber=0, likeNumber=44, createdTime=2022-01-25, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=656829456957, moduleTitle=UCB正在寻求IL-17A 和 IL-17F 双重抑制剂Bimzelx在银屑病关节炎中的批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=656829456957)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508321, encodeId=e463150832179, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=Nat Biomed Eng：给免疫系统踩油门，MIT开发IL-12+明矾疗法，高效杀伤肿瘤，且副作用更低, objectType=article, longId=294243, objectId=b57629424374, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b57629424374, replyNumber=0, likeNumber=24, createdTime=2022-01-20, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b57629424374, moduleTitle=Nat Biomed Eng：给免疫系统踩油门，MIT开发IL-12+明矾疗法，高效杀伤肿瘤，且副作用更低, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b57629424374)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508320, encodeId=fd7c1508320d1, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=Br J Dermatol：IL-1家族细胞因子治疗慢性炎症性皮肤病的潜力, objectType=article, longId=294161, objectId=9bc929416155, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bc929416155, replyNumber=0, likeNumber=36, createdTime=2022-01-19, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bc929416155, moduleTitle=Br J Dermatol：IL-1家族细胞因子治疗慢性炎症性皮肤病的潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9bc929416155)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508319, encodeId=a253150831971, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=Cardiovasc Diabetol：IL-12/23p40水平升高可作为2型糖尿病心率变异性功能障碍的潜在指标, objectType=article, longId=293933, objectId=3de72939337a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3de72939337a, replyNumber=0, likeNumber=25, createdTime=2022-01-14, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3de72939337a, moduleTitle=Cardiovasc Diabetol：IL-12/23p40水平升高可作为2型糖尿病心率变异性功能障碍的潜在指标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3de72939337a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508318, encodeId=3781150831817, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=Front Immunol：Antcin K抑制滑膜成纤维细胞TNF-α、IL-1、IL-8的表达并改善软骨退化, objectType=article, longId=293814, objectId=5f1529381446, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f1529381446, replyNumber=0, likeNumber=0, createdTime=2022-01-12, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f1529381446, moduleTitle=Front Immunol：Antcin K抑制滑膜成纤维细胞TNF-α、IL-1、IL-8的表达并改善软骨退化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f1529381446)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508317, encodeId=27a3150831e22, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=Science Immunology：彭华/傅阳心合作开发新一代高效低毒肿瘤特异性IL-12前体药物, objectType=article, longId=293651, objectId=d6b329365133, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6b329365133, replyNumber=0, likeNumber=38, createdTime=2022-01-11, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6b329365133, moduleTitle=Science Immunology：彭华/傅阳心合作开发新一代高效低毒肿瘤特异性IL-12前体药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d6b329365133)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508316, encodeId=bd3d1508316f9, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=LEO Pharma宣布FDA核准Adbry™ (tralokinumab)作为特异性靶向作用于中度至重度特应性皮炎成人IL-13的治疗药物, objectType=article, longId=293187, objectId=acae29318e52, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=acae29318e52, replyNumber=0, likeNumber=42, createdTime=2022-01-01, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=acae29318e52, moduleTitle=LEO Pharma宣布FDA核准Adbry™ (tralokinumab)作为特异性靶向作用于中度至重度特应性皮炎成人IL-13的治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=acae29318e52)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508315, encodeId=9f001508315c4, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=AIM2和NLRP3炎症小体在辐射期间诱发IL-1介导的抗肿瘤作用, objectType=article, longId=221273, objectId=eb042212e30b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb042212e30b, replyNumber=0, likeNumber=26, createdTime=2021-12-01, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb042212e30b, moduleTitle=AIM2和NLRP3炎症小体在辐射期间诱发IL-1介导的抗肿瘤作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb042212e30b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508314, encodeId=04df15083144f, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=ARD: 对IL-1和IL-6抑制剂的严重迟发性超敏反应与常见的HLA-DRB1*15等位基因有关, objectType=article, longId=220737, objectId=608e220e37c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=608e220e37c3, replyNumber=0, likeNumber=35, createdTime=2021-11-23, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=608e220e37c3, moduleTitle=ARD: 对IL-1和IL-6抑制剂的严重迟发性超敏反应与常见的HLA-DRB1*15等位基因有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=608e220e37c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

IL-1

2020-05-29

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

Am J Clin Dermatol：IL-12/23、IL-17和IL-23抑制剂治疗银屑病的药物存活率

2022-08-24

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

IL-13通过抑制肺动脉平滑肌细胞增殖、调节巨噬细胞浸润缓解特发性肺动脉高压

2022-08-15

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

ARD：IL-12/23通路抑制剂优特克单抗或TNFi 治疗银屑病关节炎患者的持久性和有效性相当

2022-06-30

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

A&R：CD163+ M2巨噬细胞通过Toll样受体7/IL-1受体相关激酶4/NF-κB信号通路促进IgG4相关疾病的纤维化

2022-05-12

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

A&R: IL-13Rα1介导的信号传导调节年龄相关/自身免疫 B 细胞扩增和狼疮发病机制

2022-05-02

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

托法替尼对银屑病患者皮肤和血液中IL-12/IL-23 p40亚单位的抑制依赖于树突状细胞中活性干扰素-γ信号传导研究

2022-04-29

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

Crit Care：伴有AKI的危重患者血清IL-17水平较高且与患者较差预后相关

2022-04-17

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

Front Immunol：IL-17加重慢性阻塞性肺疾病急性加重期铜绿假单胞菌呼吸道感染

2022-03-14

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

Br J Dermatol：Brodaluma阻断 IL-17RA可减少化脓性汗腺炎皮肤和血清中的炎症通路

2022-03-06

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

Front Immunol：大疱性类天疱疮的IL-13遗传易感性：治疗的潜在目标和预后标志物

2022-02-17

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

Nature Medicine：令人兴奋：IL-15超级激动剂治疗艾滋病的1期临床结果发布

2022-02-05

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

UCB正在寻求IL-17A 和 IL-17F 双重抑制剂Bimzelx在银屑病关节炎中的批准

2022-01-25

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

Nat Biomed Eng：给免疫系统踩油门，MIT开发IL-12+明矾疗法，高效杀伤肿瘤，且副作用更低

2022-01-20

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

Br J Dermatol：IL-1家族细胞因子治疗慢性炎症性皮肤病的潜力

2022-01-19

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

Cardiovasc Diabetol：IL-12/23p40水平升高可作为2型糖尿病心率变异性功能障碍的潜在指标

2022-01-14

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

Front Immunol：Antcin K抑制滑膜成纤维细胞TNF-α、IL-1、IL-8的表达并改善软骨退化

2022-01-12

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

Science Immunology：彭华/傅阳心合作开发新一代高效低毒肿瘤特异性IL-12前体药物

2022-01-11

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

LEO Pharma宣布FDA核准Adbry™ (tralokinumab)作为特异性靶向作用于中度至重度特应性皮炎成人IL-13的治疗药物

2022-01-01

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

AIM2和NLRP3炎症小体在辐射期间诱发IL-1介导的抗肿瘤作用

2021-12-01

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

ARD: 对IL-1和IL-6抑制剂的严重迟发性超敏反应与常见的HLA-DRB1*15等位基因有关

2021-11-23

科室
- - 订阅+
  - 更多科室
工具
服务